Immunity Inflammation and Disease · 2013 · 90 citations · 53 references
Veterinary MedicineImmunologyInfectious DiseasesHost-pathogen InteractionsImmunology Of Infectious DiseasesInflammationCytokine BiologyImmune Responses To InfectionImmunopathology Of Infectious DiseasesInflammation In Infectious DiseaseInflammatory SignalingInnate Immune ResponseAcute Lung InflammationHost Response MarkersHost-pathogen Cytokine InteractionsImmune Response To Bacterial InfectionInterleukin-1 Family CytokinesInterleukin-1 Family SignalingMycobacterium Tuberculosis InfectionMycobacterium Tuberculosis Pathogenesis
TNF and IL-1 are major mediators involved in severe inflammatory diseases against which therapeutic neutralizing antibodies are developed. However, both TNF and IL-1 receptor pathways are essential for the control of Mycobacterium tuberculosis infection, and it is critical to assess the respective role of IL-1α, IL-1β, and TNF. Using gene-targeted mice we show that absence of both IL-1α and IL-1β recapitulates the uncontrolled M. tuberculosis infection with increased bacterial burden, exacerbated lung inflammation, high IFNγ, reduced IL-23 p19 and rapid death seen in IL-1R1-deficient mice. However, presence of either IL-1α or IL-1β in single-deficient mice is sufficient to control acute M. tuberculosis infection, with restrained bacterial burden and lung pathology, in conditions where TNF deficient mice succumbed within 4 weeks with overwhelming infection. Systemic infection by attenuated M. bovis BCG was controlled in the absence of functional IL-1 pathway, but not in the absence of TNF. Therefore, although both IL-1α and IL-1β are required for a full host response to virulent M. tuberculosis, the presence of either IL-1α or IL-1β allows some control of acute M. tuberculosis infection, and IL-1 pathway is dispensable for controlling M. bovis BCG acute infection. This is in sharp contrast with TNF, which is essential for host response to both attenuated and virulent mycobacteria and may have implications for anti-inflammatory therapy with IL-1β neutralizing antibodies.
53
Characterization of tumor necrosis factor-deficient mice
Michael W. Marino, Ashley R. Dunn, Dianne Grail et al. · Proceedings of the National Academy of Sciences · 1997 · 793 citations
Life Sciences, Immunology, Pathology +17